BR112022022352A2 - Polipeptídeos que se ligam à pd-1 canina e usos dos mesmos - Google Patents

Polipeptídeos que se ligam à pd-1 canina e usos dos mesmos

Info

Publication number
BR112022022352A2
BR112022022352A2 BR112022022352A BR112022022352A BR112022022352A2 BR 112022022352 A2 BR112022022352 A2 BR 112022022352A2 BR 112022022352 A BR112022022352 A BR 112022022352A BR 112022022352 A BR112022022352 A BR 112022022352A BR 112022022352 A2 BR112022022352 A2 BR 112022022352A2
Authority
BR
Brazil
Prior art keywords
polypeptides
canine
bind
bind canine
vhh
Prior art date
Application number
BR112022022352A
Other languages
English (en)
Portuguese (pt)
Inventor
Pandit Rajay
C Timmer John
P Eckelman Brendan
Deveraux Quinn
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of BR112022022352A2 publication Critical patent/BR112022022352A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112022022352A 2020-05-04 2021-05-03 Polipeptídeos que se ligam à pd-1 canina e usos dos mesmos BR112022022352A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063019817P 2020-05-04 2020-05-04
PCT/US2021/030476 WO2021225961A1 (en) 2020-05-04 2021-05-03 Canine pd-1-binding polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
BR112022022352A2 true BR112022022352A2 (pt) 2023-01-10

Family

ID=76076497

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022022352A BR112022022352A2 (pt) 2020-05-04 2021-05-03 Polipeptídeos que se ligam à pd-1 canina e usos dos mesmos

Country Status (10)

Country Link
US (1) US20230331846A1 (https=)
EP (1) EP4146696A1 (https=)
JP (1) JP2023524995A (https=)
KR (1) KR20230005955A (https=)
CN (1) CN115776990A (https=)
AU (1) AU2021266688A1 (https=)
BR (1) BR112022022352A2 (https=)
CA (1) CA3177921A1 (https=)
MX (1) MX2022013840A (https=)
WO (1) WO2021225961A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110982824B (zh) * 2019-10-09 2022-04-15 天津大学 拮抗pd-1的抗体类似物bp基因及蛋白和应用
JP2026508096A (ja) * 2023-01-20 2026-03-10 ゾエティス・サービシーズ・ユーケー・リミテッド 治療抗体
CN120137035A (zh) * 2023-12-06 2025-06-13 北京伟杰信生物科技有限公司 一种抗犬pd-1抗体及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2541651C (en) 2003-10-22 2011-05-24 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
AU2012328819B2 (en) * 2011-10-26 2017-08-03 Elanco Tiergesundheit Ag Monoclonal antibodies and methods of use
CN106029697B (zh) * 2013-12-20 2021-06-04 英特维特国际股份有限公司 具有经修饰的ch2-ch3序列的犬抗体
US10280223B2 (en) * 2014-07-09 2019-05-07 Nippon Zenyaku Kogyo Co., Ltd. Anti-canine PD-1 antibody or anti-canine PD-L1 antibody
KR102357893B1 (ko) * 2014-08-05 2022-02-04 맵퀘스트 에스아 Pd-1 에 결합하는 면역학적 시약
CN107074952B (zh) * 2014-09-30 2021-04-09 英特维特国际股份有限公司 结合犬pd-l1的pd-l1抗体
CN120623346A (zh) * 2018-10-11 2025-09-12 因荷布瑞克斯生物科学公司 Pd-1单结构域抗体及其治疗组合物
CN110194799B (zh) * 2019-06-03 2021-07-23 北京希诺谷生物科技有限公司 结合犬pd-1的抗犬pd-1抗体

Also Published As

Publication number Publication date
CA3177921A1 (en) 2021-11-11
EP4146696A1 (en) 2023-03-15
AU2021266688A1 (en) 2022-12-08
CN115776990A (zh) 2023-03-10
JP2023524995A (ja) 2023-06-14
KR20230005955A (ko) 2023-01-10
US20230331846A1 (en) 2023-10-19
WO2021225961A1 (en) 2021-11-11
MX2022013840A (es) 2023-02-09

Similar Documents

Publication Publication Date Title
BR112021020999A2 (pt) Polipeptídeos de ligação à clec12a e usos dos mesmos
BR112022022352A2 (pt) Polipeptídeos que se ligam à pd-1 canina e usos dos mesmos
FR23C1012I2 (fr) Anticorps anti-bcma, molécules bispécifiques de liaison à un antigène liant bcma et cd3 et leurs utilisations
EP3370768A4 (en) SPECIFIC TO PD-1 BINDING ANTIBODIES AND THEIR USE
EP3958910A4 (en) Anti-cd45 antibody drug conjugates and uses thereof
MA52414A (fr) Anticorps agonistes de pd-1 et leurs utilisations
MA54539A (fr) Anticorps anti-muc16 x anti-cd28 bispécifiques et leurs utilisations
BR112022013878A2 (pt) Anticorpos que ligam integrina avb8 e utilizações dos mesmos
MA54514A (fr) Anticorps se liant à cd3
CO2020007244A2 (es) Inhibidores de kras g12c
BR112021021048A2 (pt) Polipeptídeos que se ligam a cd33 e seus usos
EP3918323A4 (en) ANTI-GAL3 ANTIBODIES AND USES THEREOF
MA54540A (fr) Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
MA44072A (fr) Anticorps se liant spécifiquement à hla-dr et leurs utilisations
EP3759143A4 (en) ANTI-TIGIT ANTIBODIES AND USES THEREOF
CY1119154T1 (el) Anti-vla-4 αντισωματα
TR201906690T4 (tr) Polipropilen Bazlı Isı-Eritmeli Yapışkan Bileşim
BR112019008494A2 (pt) anticorpos para pd-1 e usos dos mesmos
EP3710484A4 (en) CTLA-4 BINDING ANTIBODIES AND USES THEREOF
MA43308A (fr) Molécules d'anticorps se liant à april et leurs utilisations
TR201908235T4 (tr) En az bi̇r bi̇leşeni̇ kompozi̇t materyali̇n i̇şlenecek bi̇r parçasi araciliğiyla oluşturulan ayri bi̇leşenleri̇n bi̇rbi̇ri̇ne bi̇rleşti̇ri̇lmesi̇ne yöneli̇k yöntem ve zimba perçi̇ni̇
CY1125793T1 (el) Εξουδετερωτικα μορια δεσμευσης κατα της γριπης και χρησεις αυτων
BR112016007707A2 (pt) método de ligação de material particulado, método de adesão em duas superfícies e composição
UY35415A (es) Proteínas de unión a antígeno.
EP3924323A4 (en) TRICYCLODECANDIMETHANOL COMPOSITIONS AND THEIR USES

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: INHIBRX BIOSCIENCES, INC. (US)